Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 21Esophageal Squamous Cell Carcinoma 19Esophageal Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Hodgkin Disease 6Cholangiocarcinoma 6Liver Neoplasms 5Biliary Tract Neoplasms 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Advanced Solid Tumor 4Advanced Gastric Cancer 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced or Metastatic Gastric Adenocarcinoma × camrelizumab × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡